Shaping the repertoire of cytotoxic T-lymphocyte responses: Explanation for the immunodominance effect whereby cytotoxic T lymphocytes specific for immunodominant antigens prevent recognition of nondominant antigens

Blood

Volumn 93, Issue 3, 1999, Pages 952-962

  Pion, Stéphane ^b   Christianson, Gregory J ^b   Fontaine, Pierre ^a   Roopenian, Derry C ^b   Perreault, Claude ^b  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CELL DENSITY; CELL SURFACE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; T LYMPHOCYTE ACTIVATION;

EID: 0032904671     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.3.952     Document Type: Article

References (83)

1. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K: Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 11:729, 1993
2. Perreault C, Roy DC, Fortin C: Immunodominant minor histocompatibility antigens: The major ones. Immunol Today 19:69, 1998
3. b-restricted epitopes. J Immunol 157:5555, 1996
4. Deng Y, Yewdell JW, Eisenlohr LC, Bennink JR: MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J Immunol 158:1507, 1997
5. Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J: Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med 180:1471, 1994
6. Daly K, Nguyen P, Woodland DL, Blackman MA: Immunodominance of major histocompatibility complex class I-restricted influenza virus epitopes can be influenced by the T-cell receptor repertoire. J Virol 69:7416, 1995
7. b cells. J Immunol 152:4843, 1994
8. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ, Kast WM: Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154:5934, 1995
9. - strains. Proc Natl Acad Sci USA 91:11482, 1994
10. Dong T, Boyd D, Rosenberg W, Alp N, Takiguchi M, McMichael A, Rowland-Jones S: An HLA-B35-restricted epitope modified at an anchor residue results in an antagonist peptide. Eur J Immunol 26:335, 1996
11. Kageyama S, Tsomides TJ, Sykulev Y, Eisen HN: Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J Immunol 154:567, 1995
12. Levitsky V, Zhang QJ, Levitskaya J, Masucci MG: The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4. J Exp Med 183:915, 1996
13. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ: Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 156:3308, 1996
14. Sijts AJ, Villanueva MS, Pamer EG: CTL epitope generation is tightly linked to cellular proteolysis of a Listeria monocytogenes antigen. J Immunol 156:1497, 1996
15. Moudgil KD, Sekiguchi D, Kim SY, Sercarz EE: Immunodominance is independent of structural constraints. Each region within hen eggwhite lysozyme is potentially available upon processing of native antigen. J Immunol 159:2574, 1997
16. Silins SL, Cross SM, Elliott SL, Pye SJ, Burrows SR, Burrows JM, Moss DJ, Argaet VP, Misko IS: Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis. J Exp Med 184:1815, 1996
17. Steven NM, Leese AM, Annels NE, Lee SP, Rickinson AB: Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med 184:1801, 1996
18. Ugrinovic S, Mertz A, Wu P, Braun J, Sieper J: A single nonamer from the Yersinia 60-kDa heat shock protein is the target of HLA-B27-restricted CTL response in Yersinia-induced reactive arthritis. J Immunol 159:5715, 1997
19. Dudley ME, Roopenian DC: Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J Exp Med 184:441, 1996
20. Huang AY, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, Pardoll DM, Jaffee EM: The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 93:9730, 1996
21. + cytolytic T lymphocytes. J Exp Med 183:791, 1996
22. Wettstein PJ, Bailey DW: Immunodominance in the immune response to "multiple" histocompatibility antigens. Immunogenetics 16:47, 1982
23. Wettstein PJ: Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. II. Observation of a hierarchy among dominant antigens. Immunogenetics 24:24, 1986
24. Korngold R, Wettstein PJ: Immunodominance in the graft-vs-host disease T cell response to minor histocompatibility antigens. J Immunol 145:4079, 1990
25. Yin L, Poirier G, Neth O, Hsuan JJ, Totty NF, Stauss HJ: Few peptides dominate cytotoxic T lymphocyte responses to single and multiple minor histocompatibility antigens. Int Immunol 5:1003, 1993
26. Tremblay N, Fontaine P, Perreault C: T lymphocyte responses to multiple minor histocompatibility antigens generate both self-major histocompatibility complex-restricted and cross-reactive cytotoxic T lymphocytes. Transplantation 58:59, 1994
27. Brochu S, Baron C, Hetu F, Roy DC, Perreault C: Oligoclonal expansion of CTLs directed against a restricted number of dominant minor histocompatibility antigens in hemopoietic chimeras. J Immunol 155:5104, 1995
28. + T cell receptor Vβ repertoires involved in graft-versus-host disease responses to minor histocompatibility antigens. J Immunol 159:77, 1997
29. Berger M, Wettstein PJ, Korngold R: T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens. Transplantation 57:1095, 1994
30. Korngold R, Leighton C, Mobraaten LE, Berger MA: Inter-strain graft-vs.-host disease T-cell responses to immunodominant minor histocompatibility antigens. Biol Blood Marrow Transplant 3:57, 1997
31. Nelson GW, Kaslow R, Mann DL: Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection. Proc Natl Acad Sci USA 94:9802, 1997
32. Pion S, Fontaine P, Desaulniers M, Jutras J, Filep JG, Perreault C: On the mechanisms of immunodominance in cytotoxic T lymphocyte responses to minor histocompatibility antigens. Eur J Immunol 27:421, 1997
33. Perreault C, Jutras J, Roy DC, Filep JG, Brochu S: Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease. J Clin Invest 98:622, 1996
34. Wettstein PJ: Immunodominance in the T cell response to multiple non-H-2 histocompatibility antigens. III. Single histocompatibility antigens dominate the male antigen. J Immunol 137:2073, 1986
35. Greenfield A, Scott D, Pennisi D, Ehrmann I, Ellis P, Cooper L, Simpson E, Koopman P: An H-YDb epitope is encoded by a novel mouse Y chromosome gene. Nat Genet 14:474, 1996
36. Wei ML, Cresswell P: HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356:443, 1992
37. Storkus WJ, Zeh HJ, Salter RD, Lotze MT: Identification of T-cell epitopes: Rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother 14:94, 1993
38. Perreault C, Brochu S, Fontaine P, Tremblay N, Pion S: The role of MHC-associated self-peptides in transplantation and immunosurveil-lance. Clin Immunol Immunopathol 71:130, 1994
39. Morse MC, Bleau G, Dabhi VM, Hetu F, Drobetsky EA, Lindahl KF, Perreault C: The COI mitochondrial gene encodes a minor histocompatibility antigen presented by H2-M3. J Immunol 156:3301, 1996
40. Hasenkrug KJ, Cory JM, Stimpfling JH: Monoclonal antibodies defining mouse tissue antigens encoded by the H-2 region. Immunogenetics 25:136, 1987
41. Cerundolo V, Elliott T, Elvin J, Bastin J, Rammensee HG, Townsend A: The binding affinity and dissociation rates of peptides for class I major histocompatibility complex molecules. Eur J Immunol 21:2069, 1991
42. Elvin J, Potter C, Elliott T, Cerundolo V, Townsend A: A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity. J Immunol Methods 158:161, 1993
43. b that abrogates CD8 binding does not affect presentation of an immunodominant H-Y peptide. Immunology 85:74, 1995
44. + cytotoxic T cell with apparent high affinity. J Immunol 158:5797, 1997
45. Mendoza LM, Paz P, Zuberi A, Christianson G, Roopenian D, Shastri N: Minors held by majors: The HI3 minor histocompatibility locus defined as a peptide-MHC class I complex. Immunity 7:461, 1997
46. + cytotoxic T lymphocytes in association with a class I MHC protein. Cell 69:989, 1992
47. Tsomides TJ, Aldovini A, Johnson RP, Walker BD, Young RA, Eisen HN: Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med 180:1283, 1994
48. Henderson RA, Cox AL, Sakaguchi K, Appella E, Shabanowitz J, Hunt DF, Engelhard VH: Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells. Proc Natl Acad Sci USA 90:10275, 1993
49. + cytotoxic T lymphocytes. Proc Natl Acad Sci USA 92:11990, 1995
50. Bachmann MF, Oxenius A, Speiser DE, Mariathasan S, Hengartner H, Zinkernagel RM, Ohashi PS: Peptide-induced T cell receptor down-regulation on naive T cells predicts agonist/partial agonist properties and strictly correlates with T cell activation. Eur J Immunol 27:2195, 1997
51. + T cells in vitro. J Exp Med 183:2247, 1996
52. Valitutti S, Lanzavecchia A: Serial triggering of TCRs: A basis for the sensitivity and specificity of antigen recognition. Immunol Today 18:299, 1997
53. Kundig TM, Bachmann MF, Oehen S, Hoffmann UW, Simard JJ, Kalberer CP, Pircher H, Ohashi PS, Hengartner H, Zinkernagel RM: On the role of antigen in maintaining cytotoxic T-cell memory. Proc Natl Acad Sci USA 93:9716, 1996
54. Selin LK, Vergilis K, Welsh RM, Nahill SR: Reduction of otherwise remarkably stable virus-specific cytotoxic T lymphocyte memory by heterologous viral infections. J Exp Med 183:2489, 1996
55. Antoniou A, McCormick D, Scott D, Yeoman H, Chandler P, Mellor A, Dyson J: T cell tolerance and activation to a transgene-encoded tumor antigen. Eur J Immunol 26:1094, 1996
56. Valitutti S, Muller S, Cella M, Padovan E, Lanzavecchia A: Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375:148, 1995
57. Valitutti S, Muller S, Dessing M, Lanzavecchia A: Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 183:1917, 1996
58. Viola A, Lanzavecchia A: T cell activation determined by T cell receptor number and tunable thresholds. Science 273:104, 1996
59. + T cells. J Exp Med 186:757, 1997
60. Dahl AM, Beverley PC, Stauss HJ: A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J Immunol 157:239, 1996
61. Rock KL, Clark K: Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J Immunol 156:3721, 1996
62. Hurme M, Chandler PR, Hetherington CM, Simpson E: Cytotoxic T-cell responses to H-Y: Correlation with the rejection of syngeneic male skin grafts. J Exp Med 147:768, 1978
63. Oukka M, Manuguerra JC, Livaditis N, Tourdot S, Riche N, Vergnon I, Cordopatis P, Kosmatopoulos K: Protection against lethal viral infection by vaccination with nonimmunodominant peptides. J Immunol 157:3039, 1996
64. Pewe L, Wu GF, Barnett EM, Castro RF, Perlman S: Cytotoxic T cell-resistant variants are selected in a virus-induced demyelinating disease. Immunity 5:253, 1996
65. Pion S, Fontaine P, Baron C, Gyger M, Perreault C: Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy. J Clin Invest 95:1561, 1995
66. Speiser DE, Kyburz D, Stubi U, Hengartner H, Zinkernagel RM: Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection. J Immunol 149:972, 1992
67. Alexander-Miller MA, Leggatt GR, Berzofsky JA: Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 93:4102, 1996
68. Stuhler G, Walden P: Collaboration of helper and cytotoxic T lymphocytes. Eur J Immunol 23:2279, 1993
69. + T cell help. J Exp Med 186:65, 1997
70. Stuhler G, Schlossman SF: Antigen organization regulates cluster formation and induction of cytotoxic T lymphocytes by helper T cell subsets. Proc Natl Acad Sci US A 94:622, 1997
71. Lombardi G, Sidhu S, Batchelor R, Lechler R: Anergic T cells as suppressor cells in vitro. Science 264:1587, 1994
72. Frasca L, Carmichael P, Lechler R, Lombardi G: Anergic T cells effect linked suppression. Eur J Immunol 27:3191, 1997
73. Davies JD, Leong LY, Mellor A, Cobbold SP, Waldmann H: T cell suppression in transplantation tolerance through linked recognition. J Immunol 156:3602, 1996
74. Blanchard DK, Wei S, Duan C, Pericle F, Diaz JI, Djeu JY: Role of extracellular adenosine triphosphate in the cytotoxic T-lymphocyte-mediated lysis of antigen presenting cells. Blood 85:3173, 1995
75. + T cells limits their cytokine synthesis and proliferation. J Exp Med 184:1543, 1996
76. Stenger S, Mazzaccaro RJ, Uyemura K, Cho S, Barnes PF, Rosat JP, Sette A, Brenner MB, Porcelli SA, Bloom BR, Modlin RL: Differential effects of cytolytic T cell subsets on intracellular infection. Science 276:1684, 1997
77. Tanchot C, Lemonnier FA, Perarnau B, Freitas AA, Rocha B: Differential requirements for survival and proliferation of CD8 naive or memory T cells. Science 276:2057, 1997
78. Iezzi G, Karjalainen K, Lanzavecchia A: The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 8:89, 1998
79. +) T cells. J Exp Med 185:2133, 1997
80. Ehl S, Klenerman P, Aichele P, Hengartner H, Zinkernagel RM: A functional and kinetic comparison of antiviral effector and memory cytotoxic T lymphocyte populations in vivo and in vitro. Eur J Immunol 27:3404, 1997
81. + T cells in primary and secondary influenza pneumonia. Immunity 8:683, 1998
82. Wucherpfennig KW, Strominger JL: Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695, 1995
83. Barnaba V: Viruses, hidden self-epitopes and autoimmunity. Immunol Rev 152:47, 1996